Skip to content
Medxy AI Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • news
  • Page 52
Emerging Promise of Telitacicept in Treating Systemic Lupus Erythematosus: Insights from a Phase 3 Trial
Posted inInternal Medicine news Rheumatology

Emerging Promise of Telitacicept in Treating Systemic Lupus Erythematosus: Insights from a Phase 3 Trial

Posted by MedXY By MedXY 10/25/2025
This article reviews a pivotal phase 3 trial demonstrating telitacicept's efficacy and safety in active SLE, highlighting its potential as a novel targeted therapy.
Read More
Long-Term Safety and Efficacy of Gene Therapy for Adenosine Deaminase Deficiency
Posted inAllergy & Immunology Hematology-Oncology news

Long-Term Safety and Efficacy of Gene Therapy for Adenosine Deaminase Deficiency

Posted by MedXY By MedXY 10/25/2025
This study demonstrates the long-term effectiveness and safety of autologous gene therapy for treating ADA deficiency, showing sustained immune function and minimal adverse effects over a median follow-up of 7.5 years.
Read More
Mass Azithromycin Administration in Malian Infants Shows No Mortality Benefit: A Large-Scale Randomized Trial
Posted inInfectious Diseases news Pediatrics

Mass Azithromycin Administration in Malian Infants Shows No Mortality Benefit: A Large-Scale Randomized Trial

Posted by MedXY By MedXY 10/25/2025
A large randomized trial in Mali demonstrated that mass azithromycin administration to infants aged 1–11 months did not reduce mortality compared to placebo, challenging previous findings in sub-Saharan Africa.
Read More
Emerging Promise of Sevabertinib for HER2-Mutant Non-Small-Cell Lung Cancer: A New Hope
Posted innews Oncology Respiratory

Emerging Promise of Sevabertinib for HER2-Mutant Non-Small-Cell Lung Cancer: A New Hope

Posted by MedXY By MedXY 10/25/2025
This article reviews recent clinical trial data showing sevabertinib's efficacy and safety in treating HER2-mutant NSCLC, highlighting its potential to fill an unmet therapeutic gap.
Read More
Efficacy of Afatinib Combined with Chemotherapy in Post-Osimertinib EGFR-Mutated NSCLC: Insights from the NEJ025B Study
Posted innews Oncology Respiratory

Efficacy of Afatinib Combined with Chemotherapy in Post-Osimertinib EGFR-Mutated NSCLC: Insights from the NEJ025B Study

Posted by MedXY By MedXY 10/25/2025
This phase II study evaluates the effectiveness and safety of afatinib with platinum-based chemotherapy in NSCLC patients resistant to first-line osimertinib, highlighting promising outcomes and manageable toxicity.
Read More
Advancing Treatment in EGFR-Mutant NSCLC: Efficacy of Amivantamab Plus Lazertinib Post-Resistances
Posted innews Oncology Respiratory

Advancing Treatment in EGFR-Mutant NSCLC: Efficacy of Amivantamab Plus Lazertinib Post-Resistances

Posted by MedXY By MedXY 10/25/2025
This article reviews the CHRYSALIS-2 cohort A study demonstrating the potential of combined amivantamab and lazertinib therapy in heavily pretreated EGFR-mutant NSCLC patients.
Read More
Enhanced Survival in EGFR-Mutated NSCLC: The Impact of Combining Osimertinib with Chemotherapy
Posted innews Oncology Respiratory

Enhanced Survival in EGFR-Mutated NSCLC: The Impact of Combining Osimertinib with Chemotherapy

Posted by MedXY By MedXY 10/25/2025
This article reviews the latest evidence demonstrating improved overall survival with osimertinib combined with chemotherapy in first-line treatment of EGFR-mutated advanced non-small-cell lung cancer.
Read More
Enhancing Survival in Biochemically Recurrent Prostate Cancer: The Promising Role of Enzalutamide
Posted innews Oncology Urology

Enhancing Survival in Biochemically Recurrent Prostate Cancer: The Promising Role of Enzalutamide

Posted by MedXY By MedXY 10/25/2025
This review highlights the recent findings from the EMBARK trial demonstrating improved overall survival with enzalutamide combined with leuprolide in high-risk recurrent prostate cancer.
Read More
Long-Term Efficacy and Safety of Belzutifan in von Hippel-Lindau Disease-Associated Renal Cell Carcinoma: Insights from the 50-Month LITESPARK-004 Phase 2 Study
Posted innews Oncology Urology

Long-Term Efficacy and Safety of Belzutifan in von Hippel-Lindau Disease-Associated Renal Cell Carcinoma: Insights from the 50-Month LITESPARK-004 Phase 2 Study

Posted by MedXY By MedXY 10/25/2025
Belzutifan demonstrates sustained tumor response and manageable safety over 50 months in patients with von Hippel-Lindau disease-associated renal cell carcinoma, supporting its role as a systemic therapy.
Read More
DB-OTO Gene Therapy: A Breakthrough Treatment for OTOF-Related Inherited Deafness in Children
Posted innews Otorhinolaryngology Pediatrics

DB-OTO Gene Therapy: A Breakthrough Treatment for OTOF-Related Inherited Deafness in Children

Posted by MedXY By MedXY 10/24/2025
Regeneron's DB-OTO gene therapy shows promising results in restoring natural hearing in children with profound hearing loss caused by OTOF gene mutations, with 75% achieving significant hearing improvement after a single treatment.
Read More
创新口服SERD联合依维莫司疗法在晚期ER+ HER2-乳腺癌中显示优越疗效
Posted innews

创新口服SERD联合依维莫司疗法在晚期ER+ HER2-乳腺癌中显示优越疗效

Posted by MedXY By MedXY 10/24/2025
罗氏宣布giredestrant联合依维莫司的III期研究结果积极，显著降低之前接受过CDK4/6抑制剂治疗的ER+ HER2-晚期乳腺癌患者的疾病进展风险，且具有良好的安全性和生存趋势。
Read More
FDA Approves Roche’s Obinutuzumab for Lupus Nephritis: Promising Advances in B-cell Targeted Therapy
Posted inNephrology news Rheumatology

FDA Approves Roche’s Obinutuzumab for Lupus Nephritis: Promising Advances in B-cell Targeted Therapy

Posted by MedXY By MedXY 10/24/2025
The FDA has approved Roche’s obinutuzumab for active lupus nephritis in adults, offering a twice-yearly dosing regimen that achieved nearly 50% complete renal remission in trials, marking a significant advancement in lupus nephritis management.
Read More
Advances in Targeted and Gene Therapies: Promising Data on KRAS G12D Inhibitors, DR5 Agonists, and Ocular Gene Therapy
Posted inHematology-Oncology news Ophthalmology

Advances in Targeted and Gene Therapies: Promising Data on KRAS G12D Inhibitors, DR5 Agonists, and Ocular Gene Therapy

Posted by MedXY By MedXY 10/24/2025
Recent clinical trials report encouraging tumor shrinkage with KRAS G12D inhibitor VS-7375, significant progression-free survival benefit in soft tissue sarcoma with ozekibart, and a novel gene therapy acquisition targeting wet AMD.
Read More
Enhancing Surgical Outcomes: Hydrocolloid Dressings vs Petroleum Ointment for Scar Management
Posted inDermatology news Plastic Surgery

Enhancing Surgical Outcomes: Hydrocolloid Dressings vs Petroleum Ointment for Scar Management

Posted by MedXY By MedXY 10/24/2025
This clinical trial compares the effectiveness and safety of hydrocolloid dressings versus petroleum ointment in post-surgical scar healing, emphasizing patient comfort and cosmetic outcomes.
Read More
T-Cell Receptor Clonotypes as Prognostic Markers in Cutaneous T-Cell Lymphoma: Insights from Next-Generation Sequencing
Posted inDermatology Hematology-Oncology news

T-Cell Receptor Clonotypes as Prognostic Markers in Cutaneous T-Cell Lymphoma: Insights from Next-Generation Sequencing

Posted by MedXY By MedXY 10/24/2025
This study identifies specific T-cell receptor clonotypes associated with aggressive subtypes and poorer survival in mycosis fungoides and Sézary syndrome, supporting TCR sequencing as a tool for refined risk stratification in cutaneous T-cell lymphoma.
Read More
Promising Dual-Antibody Therapy Petosemtamab Shows Remarkable Response in Metastatic Colorectal Cancer
Posted innews Oncology

Promising Dual-Antibody Therapy Petosemtamab Shows Remarkable Response in Metastatic Colorectal Cancer

Posted by MedXY By MedXY 10/24/2025
Mid-phase clinical data reveal petosemtamab combined with FOLFOX/FOLFIRI achieves up to 100% response in first-line left-sided metastatic colorectal cancer, with manageable safety profile and potential to address unmet needs in mCRC treatment.
Read More
Warm and Cold Risks: How Temperature Variations Impact Mortality in Swedish Heart Failure Patients
Posted inCardiology news Public Health

Warm and Cold Risks: How Temperature Variations Impact Mortality in Swedish Heart Failure Patients

Posted by MedXY By MedXY 10/24/2025
This study reveals that both low and high ambient temperatures significantly increase mortality risk among Swedish heart failure patients, highlighting the need for climate adaptation strategies in high-latitude regions.
Read More
Evaluating Pramipexole as Adjunct Therapy in Treatment-Resistant Bipolar Depression: Insights from the PAX-BD Trial
Posted innews Psychiatry

Evaluating Pramipexole as Adjunct Therapy in Treatment-Resistant Bipolar Depression: Insights from the PAX-BD Trial

Posted by MedXY By MedXY 10/24/2025
The PAX-BD trial assessed pramipexole addition to mood stabilisers in treatment-resistant bipolar depression, revealing some mood and psychosocial benefits but no significant primary outcome improvement, highlighting the need for further research.
Read More
Evaluating Serial Ketamine Infusions as Adjuncts in Inpatient Depression Care: Insights from the KARMA-Dep 2 Trial
Posted innews Psychiatry

Evaluating Serial Ketamine Infusions as Adjuncts in Inpatient Depression Care: Insights from the KARMA-Dep 2 Trial

Posted by MedXY By MedXY 10/24/2025
The KARMA-Dep 2 trial reveals that serial ketamine infusions do not significantly outperform midazolam in reducing depressive symptoms among inpatients receiving usual psychiatric care, challenging assumptions about ketamine’s long-term antidepressant benefits in this setting.
Read More
Eltrombopag in Newly Diagnosed Pediatric Immune Thrombocytopenia: A Breakthrough in Early Treatment Strategy
Posted inHematology-Oncology news Pediatrics

Eltrombopag in Newly Diagnosed Pediatric Immune Thrombocytopenia: A Breakthrough in Early Treatment Strategy

Posted by MedXY By MedXY 10/24/2025
This randomized trial demonstrates that eltrombopag significantly improves sustained platelet response in children with newly diagnosed ITP, offering a potential early intervention option.
Read More

Posts pagination

Previous page 1 … 50 51 52 53 54 … 132 Next page
  • Obstructive Coronary Artery Disease Does Not Diminish Long-Term Health Status or Clinical Efficacy After TAVR: 3-Year Insights from SCOPE I
  • Addressing the Silent Crisis: Menstrual Pain and Abnormal Bleeding as Drivers of Acute Care in Sickle Cell Disease
  • Combined Gastric Electrical Stimulation and Pyloroplasty Achieve Superior Symptom Relief in Refractory Gastroparesis
  • Shared Decision-Making with Otolaryngologists and Palliative Care Specialists Enhances Multidisciplinary Support in Advanced Oral Cavity Cancer
  • Standardizing the Digital Signal: How an Ontology of Early Warning Signs Can Predict Cytokine Release Syndrome
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

aging Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer cardiovascular disease cardiovascular health cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology exercise health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality multiple myeloma nutrition obesity older adults Pediatrics Physical Activity Pregnancy prevention prostate cancer public health randomized clinical trial randomized controlled trial randomized trial screening SGLT2 inhibitors targeted therapy type 2 diabetes weight loss women's health

Your health, we care

Copyright 2025 — Medxy AI. All rights reserved.
Scroll to Top
Sign in